Prosthesis-patient mismatch

Article written and reviewed by Dr Luca Moretti

Prosthesis-patient mismatch occurs when the effective orifice area of a normally functioning prosthetic valve is too small relative to the amount of flow required by the body. In this situation the prosthesis is not obstructed by thrombus, pannus or degeneration and the leaflets move according to design, but residual resistance remains excessive for that patient; the most typical result is therefore a high transprosthetic gradient from the time of implantation.

The concept, introduced by Rahimtoola, is relative and does not coincide with the nominal size of the prosthesis. A valve labeled 23 mm may in fact have a different area depending on the model and technique, and the same area may be adequate in a small person but insufficient in someone with a larger body surface area. To make this relationship comparable, EOAi is used, obtained by dividing effective orifice area by body surface area.

Mismatch is primarily a complication to be prevented because, once an undersized prosthesis has been implanted, medication cannot enlarge its orifice and any reintervention entails new risk. For this reason, planning before surgery or TAVI compares expected area, anatomy, the possibility of enlargement and long-term strategy, while reintervention is reserved for severe forms with clearly attributable consequences.

Diagnosis requires caution because numerous conditions can produce a high gradient and mimic mismatch: high flow, anemia, pressure recovery, Doppler errors, underexpansion, thrombosis and deterioration. A low indexed value is therefore necessary but not sufficient; chronology, leaflet motion, signal morphology and comparison with baseline must demonstrate that the prosthesis is intact but relatively small for the patient.

Hemodynamic principles, EOAi and diagnostic thresholds

The gradient across an orifice increases with the square of flow and is inversely proportional to the square of effective area. Consequently, a prosthesis with a reduced area may generate a modest resting gradient when cardiac output is low and a much larger increase during exercise. Mismatch describes this insufficient hemodynamic reserve and should therefore not be interpreted as acquired anatomical stenosis, but as an unfavorable relationship between prosthetic area and demand.

Effective orifice area is calculated with the continuity equation in aortic prostheses or obtained from validated reference values for the specific model and size, while EOAi expresses the ratio between area in cm² and body surface area in m². Before implantation, a predicted area derived from reliable tables is generally used, whereas after implantation the measured area can be calculated: two complementary quantities that answer different questions.

For the aortic position, in people with a body mass index below 30 kg/m², an EOAi above 0.85 cm²/m² is generally considered no mismatch or clinically insignificant mismatch; values from 0.66 to 0.85 indicate moderate mismatch and values up to 0.65 severe mismatch. The thresholds are clinical categories rather than a biological discontinuity: risk and gradients change along a continuum.

In obesity, body surface area overestimates flow requirement because adipose tissue does not increase flow proportionally. VARC-3 applies lower thresholds: EOAi from 0.56 to 0.70 cm²/m² for moderate mismatch and up to 0.55 for severe mismatch when BMI is at least 30 kg/m². Using standard thresholds overdiagnoses mismatch in a substantial proportion of patients with obesity.

In the mitral position, the required area is larger and commonly used thresholds classify a reduced EOAi as clinically relevant, with high severity around or below 0.9 cm²/m² and moderate mismatch between approximately 0.9 and 1.2. Heart rate, flow and compliance strongly influence the gradient; cutoffs have a less uniform evidence base than in the aortic position and should be interpreted together with imaging guidelines and the complete clinical picture.

Predicted EOAi is particularly useful in planning because it avoids some postoperative measurement errors, but its reliability depends on the quality of the reference tables. Mean values aggregated by commercial label may not represent an individual valve and some sources derive from small samples; measured EOAi instead describes actual performance in the patient but magnifies errors in outflow tract measurement and varies with flow state.

Nominal size should therefore not be used as a surrogate for effective area because the stent, sewing ring and leaflet position modify internal diameter differently. In valve-in-valve in particular, what matters is the true internal diameter of the surgical bioprosthesis rather than its external label. Catalogues, dedicated applications and CT can complement the information but do not replace a validated hemodynamic prediction.

Differential diagnosis of a high prosthetic gradient

Mismatch is present from the time of implantation and the baseline echocardiogram shows a relatively high gradient associated with a reduced indexed area, with normally mobile leaflets or occluders and values that remain substantially stable over time. A new increase developing after months or years should instead suggest prosthetic valve thrombosis, pannus or structural degeneration, although these may coexist with pre-existing mismatch.

Flow state must be documented because anemia, fever, pregnancy, fistulas, sepsis, hyperthyroidism and significant regurgitation can increase cardiac output and gradient without changing the prosthesis. Correcting or accounting for these factors may therefore normalize velocity, while blood pressure and heart rate make comparison between studies more reliable; tachycardia is particularly important in mitral prostheses, where it shortens diastole.

Technical errors can also mimic mismatch. Doppler should be aligned with the jet from multiple windows because incomplete interrogation tends to underestimate the gradient, whereas sampling a local acceleration may overestimate it; outflow tract diameter must also be measured at the appropriate location and with a consistent method across follow-up. DVI partly reduces dependence on this measurement.

In a small aorta, pressure recovery can cause the Doppler gradient, based on maximum local velocity, to exceed the net invasively measured gradient, and in selected anatomies the energy loss index may aid interpretation. Catheterization is not used routinely, however, but is reserved for cases in which discordant noninvasive data could change a reintervention decision.

Doppler profile morphology helps distinguish mismatch from acquired obstruction. In mismatch, the aortic peak tends to be early and triangular with a relatively normal acceleration time, whereas in obstruction it becomes more rounded and late-peaking; because these patterns are not absolute, CT or fluoroscopy may be required to confirm mobility and look for thrombus, pannus, underexpansion or calcification.

Low flow may mask mismatch by keeping the gradient modest and making area calculation unstable; after recovery of ventricular function, the gradient may therefore become more apparent. At the same time, an apparently reduced area under low-flow conditions may increase when output normalizes. Diagnosis should therefore integrate predicted area, morphology and serial trend, avoiding rigid application of a threshold to an unreliable measurement.

Mismatch should be distinguished from underexpansion or deformation of a transcatheter prosthesis, which fall under non-structural dysfunction. Both conditions may produce a reduced area from baseline, but in the latter there is a potentially correctable geometry; CT, by measuring the frame and eccentricity, allows risks and the possible benefit of post-dilation to be estimated.

Clinical consequences and prognostic significance

After aortic valve replacement, mismatch maintains a residual pressure load that may limit regression of hypertrophy, increase filling pressures and reduce functional recovery. The impact tends to be greater in severe forms, in younger patients with high demand, in the presence of ventricular dysfunction or other concomitant lesions, whereas moderate mismatch in a less active older patient may have more limited consequences.

Observational studies and meta-analyses have associated severe mismatch with mortality and heart failure after surgical replacement, but the magnitude of the association varies with the definition used, obesity, baseline risk and prosthesis type. Confounding is unavoidable because a small annulus, female sex, complex anatomy and comorbidities influence both the likelihood of mismatch and outcomes. This does not make the problem irrelevant, but it should be interpreted in the context of the individual patient.

Exertional dyspnea, incomplete recovery and reduced functional capacity are the most common manifestations, but they are not specific. Coronary artery disease, diastolic dysfunction, pulmonary disease, anemia and deconditioning should therefore be evaluated before attributing symptoms to the gradient; when necessary, exercise testing with hemodynamic measurements can demonstrate a disproportionate increase and reproduce the limitation.

In the mitral position, insufficient area maintains elevated atrial and pulmonary pressures and may limit the benefit of replacement. Because the gradient is strongly influenced by heart rate, rhythm and rate control have clinical relevance even though they do not change prosthetic area. Available data are less abundant and definitions less uniform than in the aortic position, which is why the report should avoid precision unsupported by the measurements.

After TAVI, severe mismatch is often less frequent than after surgery, especially with supra-annular devices and in small annuli, but it is not eliminated. Underexpansion, obesity, a very small annulus and intra-annular prostheses can still favor it, while differences between predicted and measured area and the corrections applied in obesity explain a substantial part of the variability observed across studies.

In valve-in-valve, the old ring limits expansion of the new device and makes mismatch one of the main hemodynamic concerns. A small surgical bioprosthesis, especially if already stenotic, leaves little space for the second valve and may produce a residual gradient capable of reducing benefit and durability. The strategy should therefore not be chosen solely because it avoids surgery, but on the basis of a realistic prediction of the hemodynamic result.

Prognosis is interpreted in the context of expectations and goals. Preventing severe mismatch in a young patient may provide decades of lower load; accepting a moderate gradient may be reasonable when a complex enlargement would substantially increase risk in a frail person. Prevention should reduce overall risk, not pursue the lowest echocardiographic value at any cost.

Prediction and prevention before implantation

Prevention begins before the procedure by calculating body surface area and the minimum area needed to avoid severe mismatch. Model-specific tables allow predicted EOAi to be estimated and, if the value is insufficient, the team may consider a prosthesis with a larger area, supra-annular implantation, annular enlargement, TAVI or an alternative strategy. The decision should be made before the patient goes on cardiopulmonary bypass or the device package is opened.

Aortic root or annular enlargement includes techniques that differ in extent and risk and allows implantation of a larger prosthesis, also facilitating possible future valve-in-valve procedures. The benefit must, however, be balanced against prolongation of the operation and the need for specific expertise: in appropriate patients the procedure can prevent a permanent problem, whereas in others the additional risk outweighs the benefit. Anatomy, age and center experience therefore guide the choice.

Supra-annular surgical prostheses, stentless prostheses or devices with better hemodynamics can provide a larger effective area for the same annulus. A mechanical prosthesis often provides a favorable area and high durability but requires a VKA and is not selected on the basis of gradient alone; in the mitral position, moreover, preservation of the apparatus and correct sizing must avoid interference or outflow tract obstruction.

TAVI can provide a larger area in small annuli but introduces other variables, including leak, coronary access, conduction disturbances and durability. Selection between intra-annular and supra-annular devices should therefore consider both current anatomy and future procedures, while CT sizing reduces the risk of underexpansion and malposition. In a young patient, the first TAVI should be planned together with the possibility of a second valve and the need to preserve coronary access.

When planning valve-in-valve, the model of the previous prosthesis and its true internal diameter must be identified, the area of the new device predicted and the possible feasibility of bioprosthetic valve fracture assessed. This technique can improve expansion in compatible models but is not applicable to every valve and has its own risks; coronary obstruction, annular injury and embolization must therefore be evaluated before the procedure.

In obesity, applying standard thresholds may drive more complex interventions without a true physiological need, which is why BMI-adjusted thresholds reduce the risk of overtreatment. At the opposite extreme, indexing only to body surface area may underestimate the needs of a highly active athlete; in these cases functional goals and exercise testing enter shared decision-making.

The patient should be informed about the trade-off inherent in the chosen strategy. A larger prosthesis or an additional technique may improve hemodynamics but affects operative duration, anticoagulation and future procedural options; lifetime planning therefore considers not only the area obtained with the first implant but also the effect that a possible second device might have on the residual orifice.

Management of established mismatch and follow-up

After implantation, a baseline echocardiogram is obtained under stable conditions and, if EOAi is low, measurements, model and flow state are confirmed while excluding correctable underexpansion. The report should describe grade and consequences without improperly calling an intact prosthesis “stenotic”, because this precision avoids unnecessary anticoagulation and future misdiagnoses of degeneration.

Moderate asymptomatic mismatch is followed clinically and with imaging, addressing factors that modulate the gradient such as blood pressure, anemia, heart rate and weight. Heart-failure therapy and rehabilitation can improve overall physiology without increasing area; stability during follow-up supports pure mismatch, whereas a new change requires investigation for superimposed dysfunction.

In severe symptomatic mismatch, before proposing reintervention it is necessary to demonstrate a causal link through functional and hemodynamic assessment and exclusion of relevant comorbidities. Redo risk should then be weighed against the severity of limitation and life expectancy because a patient with ventricular impairment and a substantial gradient may derive greater benefit than one whose symptoms are mainly due to pulmonary disease.

Surgical redo allows removal of the prosthesis, enlargement of the annulus and implantation of a larger device and represents the most complete correction when technically feasible, at the cost of the risks of reoperation. TAVI within a small surgical prosthesis, by contrast, may fail to resolve and sometimes worsen mismatch; for this reason it is considered only after predicting the residual gradient and evaluating possible adjunctive techniques.

When a transcatheter prosthesis is underexpanded, post-dilation may increase the area in selected cases, balancing potential benefit against risks of rupture, embolization, conduction disturbances and regurgitation. If the frame is correctly expanded but intrinsically too small, no mechanical maneuver can create new anatomical space; CT and review of the images allow the two scenarios to be distinguished.

Follow-up monitors symptoms, ventricular function, hypertrophy, pulmonary pressure, gradient, DVI and area, bearing in mind that stability over time is a characteristic of pure mismatch. A progressive increase instead suggests superimposed thrombosis, pannus or deterioration and requires the pathway for prosthetic valve dysfunction. Preserving the baseline examination therefore becomes a true diagnostic safety measure.

Optimal management arises from a simple idea: a prosthesis is chosen for a person’s flow, not merely to fill an annulus. Precision in area, indexing and differential diagnosis turns that principle into prevention. When mismatch is already present, the same precision avoids unnecessary procedures and identifies the small group in whom creating a larger orifice offers real clinical benefit.

Body surface area may change over time and should be interpreted cautiously. Weight loss, edema, amputations or other major changes alter the EOAi denominator without changing the prosthetic orifice; the initial classification should therefore refer to conditions representative of the patient, whereas non-indexed values, gradients, output and consequences carry greater weight during follow-up. Recalculating EOAi after every weight change without considering physiology risks changing the label of a prosthesis that has remained identical.

Sex does not directly modify thresholds, but women more often have small annuli and may therefore receive nominally smaller prostheses. Indexing corrects part of this difference, while accurate anatomical planning prevents greater technical difficulty from translating into a less effective hemodynamic result. Prognostic associations should also be adjusted for body size and comorbidities so that sex is not blamed for what mainly depends on area and geometry.

Exercise capacity is a particularly sensitive measure in young or active patients because, as output increases, the gradient across a small area rises nonlinearly and may explain dyspnea that is absent at rest. Stress echocardiography records symptoms, blood pressure, output and gradient, but an isolated increase does not constitute an intervention threshold: the value of the test lies in demonstrating the causal relationship and comparing it with ventricular and pulmonary reserve.

In registries, the prevalence of mismatch changes substantially depending on whether predicted or measured EOAi is used. Echocardiographic measurement reflects individual performance but introduces technical variability, whereas tables provide a more stable classification without necessarily describing the actual performance of the individual device. Studies and reports should therefore specify the method, reference model and obesity adjustment because, without this information, comparing percentages across centers or prostheses is methodologically fragile.

The quality of prevention can also be audited by recording predicted EOAi, frequency of severe mismatch, use of annular enlargement, discharge gradients and outcomes by anatomical class. A very low rate is not automatically a better quality indicator if it results from excluding patients with small annuli or from disproportionately risky procedures; the figure should be adjusted for case mix and interpreted together with mortality, complications and quality of life. The goal is not to eliminate every moderate form but to prevent avoidable severe mismatch without increasing overall procedural harm.

At the transition from hospital to follow-up, the report should specify whether mismatch grade is predicted or measured, which BMI was used and under what flow conditions the measurements were obtained. This simple discipline prevents a label from later being reinterpreted as acquired stenosis and provides the cardiologist with a coherent reference for subsequent examinations.